These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37271529)

  • 41. Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks.
    Castaman G; Linari S
    Expert Rev Hematol; 2018 Jul; 11(7):567-576. PubMed ID: 29886751
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy.
    Kumar R; Dunn A; Carcao M
    Semin Thromb Hemost; 2016 Feb; 42(1):18-29. PubMed ID: 26771678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of prothrombin complex concentrates in the treatment of hemophiliacs with factor VIII inhibitors.
    Lusher JM
    Scand J Haematol Suppl; 1984; 40():195-202. PubMed ID: 6433452
    [No Abstract]   [Full Text] [Related]  

  • 44. Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients.
    Ar MC; Balkan C; Kavaklı K
    Turk J Haematol; 2019 Aug; 36(3):141-154. PubMed ID: 31088040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
    Leissinger CA
    Am J Hematol; 2004 Oct; 77(2):187-93. PubMed ID: 15389908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S
    Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging drugs for hemophilia A: insights into phase II and III clinical trials.
    Kizilocak H; Young G
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):337-350. PubMed ID: 34601977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies.
    Peyvandi F; Berger K; Seitz R; Hilger A; Hecquet ML; Wierer M; Buchheit KH; O'Mahony B; Bok A; Makris M; Mansmann U; Schramm W; Mannucci PM
    Haematologica; 2020 Aug; 105(8):2038-2043. PubMed ID: 32467138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?
    Ellsworth P; Ma A
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):219-225. PubMed ID: 34889356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advances and dilemmas in recombinant blood products.
    Schaefer J
    J Infus Nurs; 2002; 25(5):305-9. PubMed ID: 12355055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The promise and challenges of bioengineered recombinant clotting factors.
    Pipe SW
    J Thromb Haemost; 2005 Aug; 3(8):1692-701. PubMed ID: 16102035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hematological treatment and prophylaxis in patients with and without inhibitors.
    Marco-Rico A
    Blood Coagul Fibrinolysis; 2023 Jun; 34(S1):S9-S11. PubMed ID: 37254723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
    Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
    Buchanan GR; Kevy SV
    Pediatrics; 1978 Nov; 62(5):767-74. PubMed ID: 724319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Gray E; Kitchen S; Bowyer A; Chowdary P; Jenkins PV; Murphy P; Platton S; Riddell A; Lester W
    Haemophilia; 2020 Jan; 26(1):6-16. PubMed ID: 31846168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors.
    Abildgaard CF; Britton M; Harrison J
    J Pediatr; 1976 Feb; 88(2):200-5. PubMed ID: 1249680
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune tolerance therapy in patients with acquired hemophilia.
    von Depka M
    Hematology; 2004 Aug; 9(4):245-57. PubMed ID: 15621732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nonfactor Therapies: New Approaches to Prophylactic Treatment of Haemophilia.
    Chowdary P
    Hamostaseologie; 2021 Aug; 41(4):247-256. PubMed ID: 34187062
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clotting factor concentrates].
    Barthels M; Oldenburg J
    Hamostaseologie; 2008 Dec; 28(5):387-99. PubMed ID: 19132169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.